Fundraising FoxVitranu
Columbus, US · Founded 2020 · Delaware corporation · 2 known investors
Find your way into Vitranu
Sign up to see every warm intro you have to Vitranu
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vitranu team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Vitranu develops biomaterial and biologic technologies for ophthalmic applications, particularly focused on retinal and vitreoretinal diseases. The company brings medical devices and therapeutics to market for eye care professionals and patients.
Founders & leadership
MO
Matthew OhrChief Medical OfficerMatthew Ohr previously served as Interim Chair and Retina Division Director at The Ohio State University Department of Ophthalmology. He is Chief Medical Officer of Vitranu, which develops biomaterial and biologic technologies for ophthalmic applications.
WE
Wayne EmbreeNamed on SEC filing
BB
Brad BeaseckerNamed on SEC filing
GC
Gary CharbonneauNamed on SEC filing
BP
Brian PriceDirector CMC
GB
Gordon BethwaiteStrategic Sanint Consultant
Investors · 2
Reported raises · per SEC filings
Form D private placements$1.5M disclosed across 1 round · 2021
▶$1.5MraisedOct 2021 · 13 investors · BiotechnologyRule 506(b)
▶$1.5MraisedOct 2021 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Wayne EmbreeDirector
- Gordon BethwaiteExecutive Officer, Director
- Brad BeaseckerExecutive Officer
- Gary CharbonneauDirector
- Robin SearsDirector
- Offering amount
- $3M
- Amount sold
- $1.5M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
VeratxVera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.
OisOIS is a conference and community, active since 2009, focused on eye care and ophthalmology innovation, connecting startups, strategics, investors, and clinicians. It provides curated programming, networking, and access to new technologies in the ophthalmology industry.
Arvinas Holding Co. LLCArvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology. It advances preclinical research into clinical-stage treatments for patients with limited or ineffective existing options.
Silicon RepublicCoreMap develops an electrophysiology mapping system to guide atrial fibrillation ablation procedures using electrical activation data. The company serves cardiologists and electrophysiologists treating patients with irregular heart rhythms.
Companies working in the same space as Vitranu.
Frequently asked questions
- What does Vitranu do?
- Vitranu develops biomaterial and biologic technologies for ophthalmic applications, particularly focused on retinal and vitreoretinal diseases. The company brings medical devices and therapeutics to market for eye care professionals and patients.
- Who are Vitranu's investors?
- Vitranu's investors include JobsOhio Ventures, JumpStart Equity.
- How much funding has Vitranu raised?
- Vitranu has disclosed $1.5M raised across 1 round.
- Where is Vitranu headquartered?
- Vitranu is headquartered in Columbus, US.